The patient also received parenteral antibiotics for urinary tract infection and remdesivir for covid-19 infection.The right heart failure existed prior to left ventricular assist device (lvad) implant, however, the renal function did not exist prior to lvad implant.
|
Manufacturer's investigation conclusion: a specific cause for the reported events (right heart failure, bleeding, renal dysfunction, infection, patient condition) as well as a direct correlation to heartmate 3 left ventricular assist system (lvas), serial number (b)(6), could not be conclusively be determined through this evaluation.The patient remains ongoing on heartmate 3 left ventricular assist system (lvas), serial number (b)(6), with no further issues reported at this time.The relevant sections of the device history records for (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specification.The heartmate 3 left ventricular assist system (lvas) instructions for use (ifu) and the heartmate 3 lvas patient handbook are currently available.Section 1 of the ifu, ¿introduction¿, lists right heart failure, bleeding, and renal dysfunction as potential adverse events that may be associated with the use of the heartmate 3 lvas.Section 6 of the ifu, ¿patient care and management¿, discusses the potential development of right heart failure following implant and outlines the associated treatment options.This section also provides information regarding the recommended anticoagulation regimen, including international normalized ratio (inr) values, as well as suggested anticoagulation modifications in the event that there is a risk of bleeding.Although no device-related infections were reported for this event, the ifu lists infection as an adverse event that may be associated with the use of heartmate 3 lvas.Both the ifu and patient handbook provide care instructions in regard to preventing infection.No further information was provided.The manufacturer is closing the file on this event.
|